PTC Historical Income Statement
| PTCT Stock | USD 43.23 0.34 0.79% |
Historical analysis of PTC Therapeutics income statement accounts such as Depreciation And Amortization of 248.4 M, Selling General Administrative of 366.4 M, Gross Profit of 916 M or Other Operating Expenses of 1.4 B can show how well PTC Therapeutics performed in making a profits. Evaluating PTC Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of PTC Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining PTC Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PTC Therapeutics is a good buy for the upcoming year.
PTC |
About PTC Income Statement Analysis
PTC Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to PTC Therapeutics shareholders. The income statement also shows PTC investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
PTC Therapeutics Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts PTC Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of PTC Therapeutics. It is also known as PTC Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from PTC Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into PTC Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PTC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.At this time, PTC Therapeutics' Reconciled Depreciation is comparatively stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Research Development | 540.7M | 651.5M | 666.6M | 699.9M | Total Revenue | 538.6M | 698.8M | 937.8M | 984.7M |
PTC Therapeutics income statement Correlations
Click cells to compare fundamentals
PTC Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PTC Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 12.5M | 56.4M | 86.0M | 90.9M | 129.2M | 135.6M | |
| Total Revenue | 307.0M | 380.8M | 538.6M | 698.8M | 937.8M | 984.7M | |
| Research Development | 257.5M | 477.6M | 540.7M | 651.5M | 666.6M | 699.9M | |
| Cost Of Revenue | 12.1M | 18.9M | 32.3M | 44.7M | 65.5M | 36.5M | |
| Depreciation And Amortization | 76.0M | 49.6M | 71.5M | 128.8M | 236.6M | 248.4M | |
| Selling General Administrative | 202.5M | 245.2M | 285.3M | 300.1M | 349.0M | 366.4M | |
| Gross Profit | 294.8M | 361.8M | 506.3M | 654.1M | 872.3M | 916.0M | |
| Other Operating Expenses | 499.8M | 778.6M | 913.5M | 1.1B | 1.3B | 1.4B | |
| Operating Income | (192.8M) | (397.9M) | (374.9M) | (439.9M) | (349.4M) | (331.9M) | |
| Ebit | (192.8M) | (346.6M) | (446.0M) | (496.6M) | (566.9M) | (538.6M) | |
| Ebitda | (116.8M) | (297.0M) | (374.4M) | (367.8M) | (330.3M) | (313.8M) | |
| Total Operating Expenses | 487.6M | 759.7M | 881.2M | 1.1B | 1.3B | 1.4B | |
| Income Before Tax | (239.9M) | (402.9M) | (518.3M) | (587.5M) | (696.1M) | (661.3M) | |
| Total Other Income Expense Net | (47.1M) | (59.4M) | (143.4M) | (147.6M) | (346.7M) | (329.4M) | |
| Net Income Applicable To Common Shares | (251.6M) | (438.2M) | (523.9M) | (559.0M) | (503.1M) | (478.0M) | |
| Net Income | (251.6M) | (438.2M) | (523.9M) | (559.0M) | (626.6M) | (595.3M) | |
| Income Tax Expense | 11.7M | 35.2M | 5.6M | (28.5M) | (69.5M) | (66.0M) | |
| Net Income From Continuing Ops | (251.6M) | (438.2M) | (523.9M) | (559.0M) | (641.7M) | (609.6M) | |
| Non Operating Income Net Other | 13.7M | 85.2M | (57.9M) | (49.2M) | (44.3M) | (42.1M) | |
| Tax Provision | 11.7M | 35.2M | 5.6M | (28.5M) | (87.1M) | (82.7M) | |
| Net Interest Income | (12.5M) | (56.4M) | (86.0M) | (90.9M) | (109.4M) | (103.9M) | |
| Reconciled Depreciation | 32.2M | 43.5M | 64.1M | 128.8M | 194.8M | 204.5M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.